Mitochondria have long been relegated to the role of the cell’s “powerhouse,” but a comprehensive review by Iñigo San Millán at the University of Colorado (USA), published in the journal Antioxidants (2023), argues they are actually the central negotiators of human health and longevity. The “Big Idea” presented by Iñigo San-Millán is that mitochondrial dysfunction is not merely a symptom of aging but the primary pathogenic driver behind the modern epidemic of non-communicable diseases (NCDs), including Type 2 Diabetes, Alzheimer’s, and various cancers.
The paper shifts the focus from downstream metabolic markers (like blood glucose) to the upstream bioenergetic capacity of the mitochondria. When mitochondria lose the ability to efficiently oxidize substrates—particularly lactate and fatty acids—the resulting metabolic inflexibility triggers a cascade of oxidative stress and systemic inflammation. This “bioenergetic failure” precedes clinical diagnosis by years, suggesting that mitochondrial health is the ultimate biomarker for “biological age”.
The review synthesizes decades of data to show that the metabolic characteristics of elite athletes—marked by high mitochondrial density and “metabolic flexibility”—represent the gold standard for disease prevention. Conversely, the “sedentary phenotype” results in a “clogged” electron transport chain, leading to the accumulation of reactive oxygen species (ROS) that damage cellular DNA and proteins. This bioenergetic collapse is increasingly viewed as the “common denominator” in aging.
Source:
-
Open Access Paper: The Key Role of Mitochondrial Function in Health and Disease
-
Journal/Date: Antioxidants, 2023
-
The impact score (JIF) of this journal is 6.6, and its CiteScore is 12.4 Antioxidants MDPI Journal Spotlight (2025). Evaluated against a typical high-end range of 0–60+ for top-tier general science (e.g., Nature or Science), this is a High-impact specialty journal, particularly dominant in the fields of Biochemistry and Physiology where it consistently ranks in the first quartile (Q1).
Part 2: The Biohacker Analysis
Study Design Specifications:
-
Type: Narrative and Systematic Literature Review (Synthesizing both In vivo and clinical data).
-
Subjects: Humans (ranging from sedentary individuals to professional athletes) and various murine models (C57BL/6J).
Mechanistic Deep Dive:
-
Lactate Shuttling: The paper identifies lactate as a major signaling molecule and fuel source. Dysfunctional mitochondria fail to clear lactate, leading to “lactate-induced” metabolic gridlock San-Millán (2023).
-
Mitochondrial Dynamics: Focuses on the balance of mitophagy (clearance of damaged units) and biogenesis (creation of new ones). Exercise is highlighted as the most potent activator of the PGC-1α pathway, the master regulator of mitochondrial biogenesis Exercise-Induced Benefits for Mitophagy (2021).
-
Metabolic Flexibility: The ability to switch between lipid and carbohydrate oxidation is lost in the aging/sedentary phenotype, leading to “mitochondrial gridlock” and insulin resistance.
Novelty:
The review formalizes the concept that Cardiorespiratory Fitness (CRF) is effectively a proxy for mitochondrial health. It argues for “Metabolic Rehabilitation” through specific Zone 2 exercise protocols to restore mitochondrial function as a primary treatment for chronic disease, rather than just managing symptoms with pharmaceuticals.
Critical Limitations:
-
Translational Gap: Much of the molecular mapping of the electron transport chain relies on murine tissue; human metabolic flexibility is more complex and influenced by a wider array of lifestyle variables.
-
Methodological Weakness: The review is heavily focused on exercise as the primary modality, potentially under-analyzing the role of pharmacological mitochondrial enhancers (e.g., Urolithin A, NAD+ precursors) UA and NR in Microglial Cells (2024).
-
Missing Data: Precise “dose-response” curves for exercise-induced mitochondrial biogenesis in elderly populations remain poorly defined.
From today on X: (what got me digging into this paper):
Part 3: Claims & External Verification
| Claim |
Evidence Level |
External Verification & Safety |
| Mitochondrial dysfunction is a primary driver of Type 2 Diabetes. |
Level A |
Supported by multiple meta-analyses. Mitochondrial Dysfunction in DKD (2025). |
| Zone 2 exercise (low-intensity) optimizes fatty acid oxidation. |
Level B |
Clinical trials in athletes and metabolic patients verify this physiological shift. San-Millán (2023). |
| Nicotinamide Riboside (NR) increases mitochondrial biogenesis. |
Level D (Translational Gap) |
Strong murine data; human trials show increased NAD+ but inconsistent functional improvements. NR and Mitochondrial Biogenesis Trial (2021). |
| Urolithin A enhances mitophagy in humans. |
Level B |
Specific RCTs show improved muscle strength and mitochondrial gene expression. UA and Microglial Activity (2024). |
Safety Check: High-dose NR (1,200 mg/kg in rats) showed no major toxicity, but human long-term safety above 1-2g/day is not fully established Safety Assessment of NR-E (2020).
Part 4: Actionable Intelligence
The Translational Protocol:
-
Human Equivalent Dose (HED): If using compounds like NR based on rat studies (e.g., 300 mg/kg), the HED for a 70kg human is ~3,400 mg.
-
Biomarker Panel:
-
Efficacy: Lactate clearance rate (during exercise test), Respiratory Exchange Ratio (RER), and fasting insulin.
-
Safety: Standard liver enzymes (ALT/AST) and kidney function (Cystatin C) when using research-grade mitochondrial boosters.
Feasibility & ROI:
-
Zone 2 Training: $0 cost, highest ROI. 150–300 minutes/week is the “clinical dose” for mitochondrial restoration CDC Physical Activity Guidelines (2024).
-
Sourcing: Urolithin A and NR are commercially available; purity should be verified via 3rd-party COAs.
Part 5: Strategic FAQ
-
Can metformin blunt the mitochondrial adaptations of exercise? Yes, preliminary RCT data suggests metformin may inhibit the mitochondrial biogenesis normally triggered by aerobic exercise in older adults.
-
What is the “Gold Standard” for measuring mitochondrial function in vivo? 31P Magnetic Resonance Spectroscopy (MRS) allows for non-invasive measurement of ATP synthesis and phosphocreatine recovery San-Millán Review (2023).
-
Does the paper advocate for high-intensity interval training (HIIT)? It acknowledges HIIT for “maximal power,” but prioritizes Zone 2 for “metabolic base” and lipid oxidation efficiency.
-
Are there contraindications for mitochondrial antioxidants? Excessive supplementation (e.g., high-dose Vitamin E/C) can actually blunt beneficial “mitohormetic” signaling from exercise.
-
How does cGAS-STING relate to mitochondrial health? Leaky mitochondrial DNA (mtDNA) into the cytoplasm triggers the cGAS-STING pathway, causing sterile inflammation (inflammaging) UA and cGAS-STING (2024).
-
Is lactate clearance a viable biohack? Monitoring blood lactate during training (target <2.0 mmol/L) is a direct proxy for mitochondrial aerobic capacity.
-
What is the role of CoQ10? It is essential for electron transport; however, supplemental efficacy varies wildly by formulation (Ubiquinol vs. Ubiquinone).
-
Does “mitophagy” decrease with age? Yes, the accumulation of “zombie” mitochondria is a hallmark of the aging phenotype.
-
Can diet alone fix mitochondria? Caloric restriction (CR) and ketogenic diets can improve efficiency, but exercise remains the only known way to significantly increase mitochondrial volume.
-
What data is still missing? Longitudinal human data linking specific mitochondrial “scores” to actual lifespan (years lived) is currently absent. [Confidence: Medium]
Follow-on Prompt:
To what degree might the peptide SS-31 mitigate the age-related mitochondrial dysfunction that is mentioned in the previous paper?
Gemini Pro
SS-31 (Elamipretide): The “Molecular Stent” for Mitochondrial Gridlock
Based on the mechanistic failures identified in the San-Millán paper—specifically “bioenergetic gridlock” and the inability to oxidize substrates—the peptide SS-31 (Elamipretide) represents a high-precision, pharmacological countermeasure.
While San-Millán advocates for “Zone 2” training to remodel mitochondria through biogenesis (making more mitochondria), SS-31 works by optimizing the efficiency of the mitochondria you already have. It acts as a structural stabilizer for the inner mitochondrial membrane (IMM), effectively serving as a “molecular stent” to unclog the electron transport chain.
Here is an analysis of to what degree SS-31 mitigates the specific dysfunctions cited in the paper:
1. The Core Mechanism: Unclogging the Electron Transport Chain
San-Millán describes a “clogged” metabolic state where electrons cannot flow efficiently to Oxygen, leading to lactate buildup and ROS generation. SS-31 directly addresses this structural failure.
-
The Target: SS-31 binds exclusively to Cardiolipin (CL), a phospholipid unique to the IMM that acts as the “glue” holding the Electron Transport Chain (ETC) supercomplexes together.
-
The Fix: In aging, Cardiolipin becomes oxidized and creates “gaps” in the chain, causing electron leaks (ROS) and reduced ATP. SS-31 stabilizes Cardiolipin, tightening the supercomplexes.
-
The Result: This “tightening” restores electron flow, directly mitigating the “gridlock.” In aged human skeletal muscle, a single infusion of SS-31 was shown to restore **** (maximal ATP production) to levels comparable to younger adults In vivo mitochondrial ATP production is improved after a single dose (2021).
2. Mitigation of Specific “San-Millán” Dysfunctions
| Dysfunction (San-Millán) |
SS-31 Mitigation Potential |
Evidence Level |
|
“Metabolic Gridlock” (Inability to process fuel) |
High. By optimizing the ETC, SS-31 restores the electrochemical gradient required to pull substrates (like fatty acids and lactate) into the mitochondria for oxidation. |
Level B (Human In Vivo Data) |
| Lactate Accumulation |
Moderate. Rat models of ischemic stress show SS-31 significantly lowers blood lactate levels, suggesting it restores aerobic respiration capacity, the exact goal of Zone 2 training. |
Level D (Animal Data) Decreased Lactate in Rats (2018)
|
| ROS & Inflammation |
Very High. Unlike standard antioxidants (Vitamin C/E) which indiscriminately scavenge ROS, SS-31 prevents ROS at the source (Electron Leak) without blunting necessary signaling. This directly stops the “sterile inflammation” San-Millán links to cancer and diabetes. |
Level B (Human/Mouse Consensus) |
| Loss of Mitochondrial Mass |
Low. Critical Distinction: SS-31 improves quality (efficiency per mitochondrion) but does not induce biogenesis (quantity). It will not replace the volume-building effects of exercise. |
Level D (Murine Data) |
3. The Translational Gap: “Quality vs. Outcome”
While the mechanistic match is nearly perfect, the clinical reality is nuanced.
-
The Success: In aged mice, SS-31 reverses age-related redox stress and improves exercise tolerance without exercise Improving mitochondrial function in aged mice (2019).
-
The Failure: In the Phase 3 MMPOWER-3 trial for Primary Mitochondrial Myopathy (PMM), Elamipretide failed to significantly improve the 6-Minute Walk Test (6MWT) compared to placebo, despite its success in Phase 2 MMPOWER-3 Trial Results (2023).
-
The Takeaway: There may be a threshold where “fixing” the electron transport chain pharmacologically is not enough to overcome severe systemic muscle atrophy (sarcopenia) without the mechanical stimulus of resistance or Zone 2 training.
Summary Verdict
SS-31 is likely the most potent pharmacological tool currently available to reverse the bioenergetic efficiency defects described by San-Millán. However, it is a partial mimetic: it restores the “engine tuning” (efficiency) but does not build a “bigger engine” (biogenesis) like exercise does.
Related Reading:
1 Like
